Moreover, Rodenhuis et al (2003) in the National Duch trial of high-dose chemotherapy in high-risk breast cancer have reported an unplanned subset analysis based on HER-2 status suggesting that the improvement of relapse-free survival of high-dose chemotherapy in patients with stage II and III breast cancer and 10 or more axillary nodes may be confined to patients with HER-2-negative tumours. Here, ERBB2 is linked to breast carcinoma.